Adamas Pharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
August 27, 2015 16:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas...
Adamas Reports Second Quarter 2015 Financial Results
August 11, 2015 16:04 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the second quarter of 2015. The company reported a net loss...
Adamas Completes Recruitment of Its Phase 3 EASE LID Study Evaluating ADS-5102 for the Treatment of Levodopa-induced Dyskinesia Associated With Parkinson's Disease
July 09, 2015 16:10 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of recruitment of its Phase 3 EASE LID study. EASE LID is a confirmatory...
Adamas Pharmaceuticals Issued U.S. Patent Relating to ADS-5102 Program
July 07, 2015 16:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No....
Adamas Pharmaceuticals to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
June 24, 2015 16:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 24, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas...
Adamas Announces Additional Findings From Its Phase 2/3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson's Disease
June 15, 2015 15:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional findings from its Phase 2/3 study (EASED) evaluating ADS-5102 for the...
Adamas Begins Phase 2 Clinical Trial Assessing ADS-5102 for Treating Multiple Sclerosis Symptoms in Patients With Walking Impairment
June 11, 2015 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today the initiation of a Phase 2 clinical trial with ADS-5102 (amantadine HCl) in...
Adamas Pharmaceuticals to Present at the 2015 JMP Securities Life Science Conference
June 09, 2015 16:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas...
Adamas Reports First Quarter 2015 Financial Results
May 13, 2015 16:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the first quarter of 2015.
"In 2015, we have made continued...
Adamas Pharmaceuticals Receives Orphan Drug Designation for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease
April 10, 2015 08:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the Food and Drug Administration (FDA) has granted orphan drug status to ADS-5102...